Player in tissue
regeneration

Discover Siltiss >

Support of the ANR

The GlycoMb project was selected in 2020 by the ANR.

>

European project TBMed

Launched in February 2019, this program supports SILTISS' research project on tissue regeneration.

>

SILTISS at Novaq 2018

The company SILTISS participated in the Novaq innovation festival, from September 13 to 15 2018 in Bordeaux.

>
Read all the news >

Company

our business

SILTISS is dedicated to the development, production and marketing of non-animal biomimetic biomaterials, which promote and support tissue regeneration processes.

The initial applications relate to bone substitutes for the orthopedic and dental sectors as well as maxillofacial surgery.

Discover Siltiss>

Strategy

strong commitments

Innovation.

The technology provided by SILTISS is protected by several patents and is the result of a close partnership with Inserm.

Expertise.

The team is led by Didier Letourneur, CNRS Research Director and Director of U1148 Inserm, located in Paris, and awarded the George Winter Prize by the European society of biomaterials.

Safety.

The quality management system follows the requirements of the medical device regulation (ISO 13485) which guarantees the marketing of safe and effective products.

Products

a unique offer

Natural hydrogels of<br>non-animal origin

Natural hydrogels of
non-animal origin

Biomaterials that are biocompatible and of variable porosity

Biomaterials that are biocompatible and of variable porosity

Biodegradable and biomimetic environment

Biodegradable and biomimetic environment

100% developed and produced in France

100% developed and produced in France